Pancreatic Metastasis from RCC mimicking PNET
DISCLOSURE OF INTEREST

- No conflicts of interest.
Initial Presentation

- 64-year-old Male
- PS 0
- Comorbid: T2DM, HT, Hypothyroidism

Present with Facial plethora
- Polycythemia (Hb 20 / Hct 61)
- JAK2 V617F neg

- CT (29/10/2008): Lt. Renal mass 7.1x6.9 cm, no LN, no distant metastasis
- Lt. Radical Nephrectomy (19/11/2008)
  - Clear cell RCC gr.II
- Dx: Clear cell RCC pT2N0M0
1st Line Rx Metastatic RCC

- **September 2011**: LLL Pulmonary nodule 2.1x1.8 cm
- **October 2011**: LLL Lobectomy (13/10/2011)
  - Metastatic clear cell carcinoma

**Dx**: Recurrent clear cell RCC with Pulmonary metastasis
- MSKCC - Favourable risk

- **January 2012**: start Sunitinib 50 mg/d x 4-wk on/2-wk off
  - Stomatitis gr.2, HFSR gr.3 —> ↓ Sunitinib 37.5 mg/d
  - January 2012 - September 2017 —> **PR**
Pancreatic Metastasis from RCC

- **May 2017**: Pancreatic mass 1.9x1.5 cm —> MDT: Wait&See
- **October 2017**: Pancreatic mass 3.0x2.1 cm
- **November 2017**: Distal Pancreatectomy (30/11/2017)
  - Clear cell RCC
  - Complication: Intraabdominal collection, Fistula
2nd line Rx Metastatic RCC

- July 2018: Liver metastasis at segment 2/3 and 6
  - PS 1
- August 2018: start Axitinib 5mg BID
- August 2018 - June 2019: SD
ESMO PRECEPTORSHIP PROGRAMME

Complication
Intrabdominal collection
Fistula

Lt.Radical Nephrectomy
November 2008

Sunitinib
January 2012 - September 2017

Axitinib
July 2018 - Present

RCC pT2N0M0

Metastectomy
LLL Lobectomy
October 2011

RCC rT0N0M1

Distal Pancreatectomy
November 2017

PR
69 mo.

CR

SD
> 12 mo.

ESMO PRECEPTORSHIP PROGRAMME
Thank you for your attention!